Andrew Smith

September 26, 2019

Aaron Kowalski, PhD, the new CEO of the JDRF, says in a discussion about insulin pricing that action is needed not only by Congress, but also by insulin makers, health plans, and the executive branch. The most important goal: ending a crosspayment scheme that many blame for potentially deadly price increases.

December 07, 2018

Evidence-Based OncologyTM sat down with Andrew W. Lo, PhD, to discuss his proposals to increase investment in medical innovation and utilization by giving investors more ways to support both research organizations and individual patients.

December 18, 2017

Evidence is more robust on kidney function but not sufficient to make drug decisions, one expert said. A whole separate trial, called CREDENCE, is examining renal function in patients taking canagliflozin.

September 23, 2017

UnitedHealthcare has not released numbers on how many patients are affected by its exclusivity deal with Medtronic. While the initial press stories criticizing the transaction have died down, a JDRF initiative calls on insurers to preserve patient choice.

September 22, 2017

An experienced market watcher who has diabetes predicts the key to success will come down to one factor: ease of use.

June 22, 2017

An expert discusses her research on a critical period for patients with type 1 diabetes: moving from having parents make care decisions to taking control of disease management.

December 14, 2016

A leading diabetes educator discusses how the role of nutrition has evolved and how payers can do more to promote the role of education in helping patients improve their diets.

December 13, 2016

A recent report from the Government Accountability Office mostly concurs with CMS on a dispute over problems with the Medicare competitive bidding program, following an explosive study in Diabetes Care that found beneficiaries lost access to key supplies.

September 23, 2016

Second of 2 Parts: See Part 1, in Evidence-Based Diabetes Management, coverage of Patient-Centered Diabetes Care 2016.

September 21, 2016

For some patients newly diagnosed with type 2 diabetes, skipping metformin monotherapy and going straight to fixed-dose combinations with a DPP-4 inhibitor or an SGLT2 inhibitor makes sense, evidence shows.